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The prognostic implications of changes in ventricular 
ectopic activity on serial 24 hour ambulatory electro•
cardiographic (Holter) recordings were prospectively 
evaluated in 107 patients with a history of sustained 
ventricular tachyarrhythmias treated with amiodarone 
for at least 30 days. Twenty-seven patients (25%) had 
insufficient ventricular ectopic activity « 1 0 ventricular 
premature complexes/h and no repetitive forms) on base•
line Holter recordings for serial statistical analysis. In 
53 (66%) of the remaining 80 patients, serial 24 hour 
Holter monitor recordings showed efficacy of treatment, 
defined as a 75 % decrease in ventricular premature com•
plexes, a 95% decrease in ventricular couplets and ab•
sence of ventricular tachycardia. During a mean follow•
up period of 14.2 ± 9.9 months, 34 (32%) of the 107 
patients had recurrence of a sustained ventricular tachy•
arrhythmia. Holter recording correctly predicted nine 
recurrences and correctly identified 37 patients who did 
not experience a recurrence. Holter efficacy failed to 
predict recurrence of a sustained ventricular tachyar•
rhythmia in 16 patients, and 18 patients remained free 
Amiodarone, a benzofuran derivative with potent antiar•
rhythmic properties, has been reported in recent studies 
(1-7) to be effective in controlling recurrent sustained ven•
tricular tachyarrhythmias in approximately 50 to 70% of 
patients in whom more conventional medical therapy was 
unsuccessful. It has been suggested (8-11) that in patients 
treated with amiodarone, in contrast to other antiarrhythmic 
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of recurrence despite failure to achieve Holter efficacy. 
The positive predictive value of Holter monitoring effi•
cacy was 33% and the negative predictive value was 
70%; however, these differences were not statistically 
significant by chi-square analysis. Similar results were 
obtained using Holter recordings performed relatively 
early in therapy (6 weeks and 4 months). 
Of the 27 patients without significant ventricular ec•
topic activity on the baseline Holter recording, 9 had an 
arrhythmia recurrence despite continued infrequent 
ventricular premature complexes and no repetitive forms 
on subsequent recordings. The recurrence rate in this 
group (33 %) was similar to the overall recurrence rate. 
Therefore, among patients taking amiodarone for 
sustained ventricular tachyarrhythmias: 1) 25% will have 
insufficient ventricular ectopic activity on 24 hour Holter 
recordings for serial statistical analysis; and 2) in the 
remaining 75%, data obtained from serial Holter re•
cordings are not predictive of arrhythmia recurrence. 
(J Am Coli CardioI1986;7:938-41) 
agents, continued inducibility of arrhythmia during serial 
electrophysiologic testing is not predictive of arrhythmia 
recurrence. Therefore, it has been proposed (6-9) that amio•
darone therapy may be empiric or directed by data obtained 
from ambulatory electrocardiographic (Holter) monitoring. 
The purpose of the present study was to prospectively de•
termine the value of suppression of spontaneous ventricular 
ectopic activity on serial Holter monitor recordings in pre•
dicting the recurrence of sustained ventricular tachycardia 
or fibrillation in patients treated with amiodarone. 
Methods 
Patients. The study group comprised 107 consecutive 
patients who had been taking amiodarone for at least 30 
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days and who had a history of either documented sustained 
ventricular tachycardia (n = 71) or cardiac arrest (n = 36) 
not associated with an acute myocardial infarction, meta•
bolic abnormalities or proarrhythmic drug effects. The clin•
ical characteristics of the patients are summarized in Table 
1. After written informed consent was obtained (protocol 
approved by the Hahnemann Institutional Review Board on 
October 1, 1981), all antiarrhythmic medication was dis•
continued for at least five half-lives and a baseline 24 hour 
two channel Holter monitor recording was performed in all 
patients. Each patient then underwent a baseline electro•
physiologic study using a previously described protocol (5). 
Amiodarone therapy was initiated after serial electrophys•
iologic testing failed to identify a single agent or combi•
nation regimen that was effective in preventing arrhythmia 
induction. Before amiodarone therapy a mean of 2.6 (range 
o to 7) drug studies were performed. 
Amiodarone administration. Amiodarone was initially 
administered either orally (n = 81) or intravenously (n = 
26). In the oral loading regimen patients received 1,000 
mg/day for the first 7 days and 800 mg/day for the next 7 
days and were then discharged receiving 600 mg/day. The 
intravenous loading regimen consisted of 10 mg/kg body 
weight per day intravenously plus 600 mg orally for the first 
3 days and 800 mg orally for the next 6 days; the patients 
were then discharged receiving 600 mg/day orally. In all 
cases electrophysiologic testing was performed after the 
loading period, and if a ventricular tachyarrhythmia that the 
patient could not tolerate remained inducible, procainamide 
or quinidine was added to the regimen and the testing was 
repeated. If the combination regimen prevented arrhythmia 
induction or if a hemodynamically tolerable tachyarrhythmia 
was inducible the patient was discharged receiving the com•
bination regimen. 
Protocol end points. The protocol end points were: 1) 
Sudden cardiac death: unexpected, witnessed death occur•
ring within 1 hour of the onset of symptoms. If the death 
was unwitnessed, the patient must have been seen within 
the previous 12 hours in his usual state of health. Patients 
resuscitated from a sustained ventricular tachyarrhythmia 
were defined as having had sudden cardiac death. Sudden 
Table 1. Characteristics of Study Group (n = 107) 
Age (yr) 
Mean ± SD 
Male/female ratio 
Left ventricular ejection fraction (%) 
Mean (range) 
Underlying disease 
Coronary artery disease 
Cardiomyopathy 
Valvular heart disease 
No organic heart disease 
Follow-up (mo) 
Mean (range) 
60.4 ± 8.8 
84/23 
26.3 (8 to 61) 
83 
22 
14.2 (2 to 37) 
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cardiac death was considered an arrhythmia occurrence. 2) 
Documented sustained ventricular tachycardia: electrocar•
diographically documented ventricular tachycardia lasting 
more than 30 seconds. 3) Nonsudden death from cardio•
vascular causes. 4) Drug discontinuation due to toxicity. 5) 
March 1, 1985. 
Follow-up. All patients were discharged taking amio•
darone, 600 mg/day, either alone or in combination with 
other agents. The patients were then seen in the arrhythmia 
clinic 1 month after discharge (6 weeks after initiation of 
amiodarone therapy), then at 4 month intervals during the 
first year and subsequently at 6 month intervals. The amio•
darone dose was decreased to 400 mg/day in those patients 
remaining in the evaluation at the 4 month follow-up clinic 
visit (13 patients had a sustained ventriculartachyarrhythmia 
recurrence between the 1 and 4 month evaluations). In 10 
patients the dose was subsequently decreased because of 
toxicity, but administration of the drug was not discontin•
ued. The clinical management of the patients was not altered 
by the results of Holter monitoring and the protocol re•
mained unaltered throughout the study. 
All patients had 24 hour Holter monitor recordings ob•
tained at baseline and at each clinic visit. In all cases a 
Holter recording was obtained within 2 months before the 
time when a protocol end point was reached. This final 
recording was used for the overall statistical analysis. In 
addition, data from Holter recordings obtained at the 1 and 
4 month clinic visits were analyzed separately to assess the 
utility of recordings obtained relatively early in the course 
of therapy. A Holter monitor recording was defined as being 
predictive of successful therapy if it showed a 75% decrease 
in ventricular premature complexes and a 95% decrease in 
ventricular couplets compared with the baseline recording 
and no episodes of ventricular tachycardia (three or more 
consecutive ventricular complexes). If these criteria were 
not met, the Holter recording was judged predictive of fail•
ure of therapy. A baseline Holter recording was considered 
to have insufficient ventricular ectopic activity for statistical 
comparison if there were fewer than 10 ventricular pre•
mature complexes/h and no repetitive forms were present. 
Statistical analysis. Statistical evaluation was per•
formed using chi-square analysis. A probability (p) value 
of 0.05 or less was considered significant. Data are ex•
pressed as the mean ± SD or the mean and the range. 
Results 
Clinical course. All 107 patients had a sustained ven•
tricular tachyarrhythmia inducible at the baseline electro•
physiologic study. In 98 patients sustained monomorphic 
ventricular tachycardia was inducible, and ventricular fi•
brillation was inducible in the remaining 9. Thirteen patients 
were discharged taking a second drug in addition to amio•
darone (procainamide in nine and quinidine in four). Thirty•
four (32%) of the 107 patients had an arrhythmia recurrence 
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during a mean follow-up period of 14.2 ± 9.9 months. The 
mean time to recurrence was 9.6 months (range 2 to 37). 
Of the 34 recurrences, II (32%) were fatal. Nine patients 
had non sudden cardiac death and in nine patients amioda•
rone was discontinued because of toxicity. The remaining 
55 patients continued taking amiodarone until the protocol 
end point. The proportion of patients on a combination 
regimen who had an arrhythmia recurrence (31 %) was sim•
ilar to that of the overall study group. 
Eighty patients (75%) had sufficient ventricular ectopic 
activity to be analyzed by serial 24 hour Holter recordings. 
On the basis of final Holter monitor data, 56 patients (66%) 
were predicted not to have a recurrence and 27 patients 
(34%) were predicted to have a recurrence. 
Holter monitoring results. Correlation of Holter mon•
itor prediction of success or failure of amiodarone therapy 
with clinical outcome is shown in Table 2. Holter analysis 
correctly predicted successful therapy in 37 patients and 
correctly predicted failure of therapy in 9. It incorrectly 
predicted successful therapy in 16 patients and incorrectly 
predicted failure of therapy in 18. The positive predictive 
value (that is, predicting recurrence) was 33% and the neg•
ative predictive value (that is, predicting no recurrence) was 
70%. However, these differences are not statistically sig•
nificant by chi-square analysis. 
Analysis of data from the J and 4 month Holter record•
ings produced similar results. The 1 month recordings cor•
rectly predicted arrhythmia recurrence in 11 of the 25 pa•
tients with a recurrence (in 9 of the total group of 34 patients 
with a recurrence, there was insufficient baseline ventricular 
ectopic activity for serial evaluation); it also correctly pre•
dicted nonrecurrence in 33 of the 55 patients who did not 
have a recurrence. The positive and negative predictive val•
ues were 33 and 70%, respectively (p = NS). The 4 month 
recordings correctly identified a subsequent recurrence in 6 
of the 17 patients with a later recurrence of arrhythmia (5 
of the patients with a recurrence between the 1 and 4 month 
evaluations had insufficient baseline ventricular ectopic ac•
tivity for serial evaluation), and correctly predicted absence 
of recurrence in 38 of the 49 patients who had no recurrence. 
Table 2. Correlation of Clinical Outcome With Overall Result 
Predicted by Holter Monitoring 
Recurrence of 
Arrhythmia 
Yes No 
A. Patients Receiving AmlOdarone Therapy Alone 
Holter momtoring predicted success of therapy 
Holter monitoring predicted failure of therapy 
16 
9 
B. Patients Receiving Combination Therapy 
Holter monitoring predicted success of therapy 
Holter monitoring predicted failure of therapy 
p = NS. 
2 
2 
37 
18 
3 
4 
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The positive and negative predictive values were 30 and 
78%, respectively (p = NS). 
A total of 27 patients (25%) had insufficient ventricular 
ectopic activity on the baseline Holter recording for serial 
analysis. The arrhythmia recurrence rate in this group was 
33%, similar to that of the overall study group and of the 
80 patients with frequent baseline ventricular ectopic activ•
ity. Of these 27 patients. 2 had nonsustained ventricular 
tachycardia «30 seconds) on subsequent Holter recordings; 
neither of these patients has had a sustained arrhythmia 
recurrence. The remaining 25 patients continued to manifest 
infrequent ventricular ectopic activity « 1 0 ventricular pre•
mature complexes/h and no repetitive forms) on serial Holter 
recordings despite a sustained ventricular tachyarrhythmia 
recurrence in 9. 
Discussion 
We have demonstrated that in patients taking amiodarone 
for otherwise medically refractory sustained ventricular 
tachyarrythmias, ventricular ectopic activity on serial 24 
hour Holter monitor recordings cannot identify patients who 
will experience an arrhythmia recurrence. Furthermore, 25% 
of patients do not have sufficient ventricular ectopic activity 
on a baseline Holter monitor recording to permit follow-up 
analysis. 
Value of Holter monitoring. Other groups have also 
investigated the utility of ambulatory electrocardiographic 
monitoring to assess efficacy of amiodarone therapy. In a 
similar patient population, Marchlinski et al. (6) obtained 
a Holter recording a mean of 11 days after initiation of 
amiodarone therapy. They found that a recording that dem•
onstrated, relative to baseline, an 85% decrease in ventric•
ular premature complex frequency and abolition of repetitive 
forms was highly predictive of successful treatment and that 
failure to meet these criteria was predictive of arrhythmia 
recurrence. This group also reported that 26% of patients 
had insufficient ventricular ectopic activity on baseline re•
cording for serial analysis. They found, as we did, that in 
patients with infrequent baseline ventricular ectopic activity 
the clinical outcome did not differ from that of patients with 
frequent ventricular ectopic activity, and that in this group 
an increase in the frequency and complexity of ventricular 
ectopic activity assessed by Holter recording was not pre•
dictive of arrhythmia recurrence. In a study of 42 patients 
with apparently less impairment of left ventricular function 
(mean ejection fraction of 36%) relative to our study group, 
Veltri et al. (7) found that the presence of ventricular tachy•
cardia on a 24 hour Holter recording obtained during 
the second week of amiodarone loading correlated with 
sustained arrhythmia recurrence. In addition, however. 
they noted that the occurrence of non sustained ventricular 
tachycardia on serial 24 hour recordings during long-term 
follow-up did not correlate with clinical outcome. Baseline 
drug-free recordings were not used for comparison and the 
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protocol for determination of amiodarone maintenance dos•
age was not clearly delineated in this particular investigation. 
Morady et al. (4) also evaluated the prognostic utility of 
a 24 hour Holter recording performed shortly after amio•
darone loading. In contrast to the studies by Marchlinski 
(6) and Veltri (7) and coworkers, they found that results of 
recordings obtained 1 week after initiation of amiodarone 
therapy were not predictive of the outcome. This group also 
did not use baseline drug-free recordings for comparison. 
In a retrospective study of a larger heterogeneous popula•
tion, Nademanee et aI. (9) reported that adjustment of chronic 
amiodarone dosage on the basis of ventricular ectopic ac•
tivity suppression on serial Holter monitor recordings re•
sulted in an "excellent" clinical response « 10% recur•
rence). They suggested that if baseline Holter recordings 
are not available or if ventricular ectopic activity is infre•
quent, amiodarone therapy can be administered empirically. 
Their results are difficult to intepret because the study pro•
tocol appears to have varied throughout the evaluation. 
Our study differs from these others in that 24 hour Holter 
monitor recordings were performed at baseline and serially 
throughout amiodarone treatment and the protocol was not 
changed during the study. In addition, patient management 
was not altered by the results of the evaluation. We believe 
that this provides a more thorough assessment of the cor•
relation of ventricular ectopic activity on Holter recordings 
with clinical outcome. 
Implications. The mechanisms of the clinical antiar•
rhythmic effect of amiodarone are not known. It has been 
demonstrated that with more conventional antiarrhythmic 
agents the occurrence of ventricular ectopic activity on am•
bulatory electrocardiographic recording does not correlate 
with spontaneously occurring sustained ventricular tachy•
cardia or fibrillation (12-14). The same appears to apply to 
amiodarone therapy. The concept that amiodarone prevents 
recurrence of sustained tachyarrhythmias by suppressing 
"triggering" ventricular ectopic activity is not supported 
by our data, but our study was not specifically designed to 
evaluate underlying mechanisms and, therefore. a conclu•
sion cannot be drawn. Marchlinski et al. (6) suggested that 
suppression of frequent ventricular ectopic activity may merely 
be a "marker" for antiarrhythmic efficacy. However, in 
our study 18 patients who had frequent ventricular ectopic 
activity including repetitive forms throughout amiodarone 
therapy did not have an arrhythmia recurrence. Conversely, 
16 patients whose ventricular ectopic activity was sup•
pressed did experience a recurrence. Therefore. on the basis 
of our results in patients treated with amiodarone for sus•
tained ventricular tachycardia or fibrillation, we conclude 
that neither suppression nor lack of suppression of ventric•
ular ectopic activity on serial 24 hour Holter recordings can 
be used to predict arrhythmia recurrence. 
Because patients with recurrent sustained ventricular 
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tachyarrhythmias treated with amiodarone have a 30 to 50% 
rate of recurrence (1-7), it would be desirable to identify 
those at high risk of drug failure so that adjunctive or al•
ternative therapy may be instituted. Recent evidence (15) 
suggests that results of programmed electrical stimulation 
may assist in identifying such patients; however, the present 
study indicates that data obtained from ambulatory electro•
cardiographic monitoring do not. 
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